Algorae buoyed by test results on dementia treatment

Dementia is categorised as a decline in cognitive function that affects a person’s ability to perform daily activities. A person with dementia has two or more specific difficulties, including decline in memory, reasoning, language, coordination, mood and behaviour.

The most common causes of dementia include Alzheimer’s disease, vascular dementia, lewy body dementia, frontotemporal dementia, Parkinson’s disease and Huntington’s disease.

Alzheimer’s disease represents about 70 per cent of all causes of dementia. Algorae says the primary focus of dementia treatment in recent decades has focused on managing symptoms and slowing the progression of the diseases underlying dementia.

As of 2020, more than 55 million people worldwide live with dementia, which is projected to triple by 2050 as average life expectancy continues to increase.

Following its latest positive test results, Algorae is planning further analysis to assess the therapeutic mechanism associated with the use of AI-116, including assessments for neuroinflammation, which management says plays a multifaceted role in the pathogenesis of neurodegenerative disorders and dementia.

Shares in Algorae jumped 20 per cent following today’s announcement to touch 1.2c during intraday trading from a previous close of 1c.

Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au